Evidence map›Paper›PMID 36978309›Full record

ArticleAntibiotics (Basel, Switzerland)2023

Effect of Quorum Sensing Molecule Farnesol on Mixed Biofilms of

Barbora Gaálová-Radochová, Samuel Kendra, Luisa Jordao, Laura Kursawe, Judith Kikhney, Annette Moter, Helena Bujdáková

Open access · goldFull text read
In one paragraph

Article in Antibiotics (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
3.7field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. The metabolic trap:Journal of medical microbiology · 2026
    Article
  3. Review
  4. Article
  5. Review
  6. Article
  7. Article
  8. MixedJournal of fungi (Basel, Switzerland) · 2025
    Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Barbora Gaálová-RadochováDepartment of Microbiology and Virology, Faculty of Natural Sciences, Comenius University in Bratislava, Ilkovičova 6, 842 15 Bratislava, Slovakia.ORCID 0000-0003-0448-4658
Samuel KendraDepartment of Microbiology and Virology, Faculty of Natural Sciences, Comenius University in Bratislava, Ilkovičova 6, 842 15 Bratislava, Slovakia.
Luisa JordaoDepartment of Environmental Health, Research and Development Unit, National Institute of Health Dr. Ricardo Jorge (INSA), Av. Padre Cruz, 1649-016 Lisboa, Portugal.ORCID 0000-0002-5608-021X
Laura KursaweBiofilmcenter, Institute of Microbiology, Infectious Diseases and Immunology, Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany.
Judith KikhneyBiofilmcenter, Institute of Microbiology, Infectious Diseases and Immunology, Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany.
Annette MoterBiofilmcenter, Institute of Microbiology, Infectious Diseases and Immunology, Charité-Universitätsmedizin Berlin, Hindenburgdamm 30, 12203 Berlin, Germany.
Helena BujdákováDepartment of Microbiology and Virology, Faculty of Natural Sciences, Comenius University in Bratislava, Ilkovičova 6, 842 15 Bratislava, Slovakia.ORCID 0000-0002-9219-0803
Comenius University Bratislava · SKCharité - Universitätsmedizin Berlin · DECS Diagnostics · DENational Institute of Health Dr. Ricardo Jorge · PT

Funding

H2020-WIDESPREAD-05-2020-Twinning 952398-CEMBOSlovak Research and Development Agency APVV-18-0075Slovak Research and Development Agency APVV-21-0302Slovak Research and Development Agency SK-PT-18-0006
6 · The paper itself

Abstract

The natural bioactive molecule farnesol (FAR) is widely studied mainly for its antibiofilm and antimicrobial properties. In addition, it increases the effectiveness of some antimicrobial substances, which makes it interesting for the development of combined therapy. In the present work, the effect of FAR either alone or in combination with oxacillin (OXA) on mixed biofilms formed by clinically relevant pathogens,

Indexed as

biofilms of C. albicans-MSSA/MRSAcell viabilityenhancing effectfarnesolmethicillin-resistant/sensitive S. aureusmicroscopyresistance

Identifiers

PMID36978309
PMCPMC10044556
OpenAlexW4321597865

What OpenQuestion holds

Textfull text, public
LicenceCC BY
reference markers read22
measurements read82
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.